Compare PROF & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROF | RCS |
|---|---|---|
| Founded | N/A | 1994 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.7M | 269.6M |
| IPO Year | 2017 | N/A |
| Metric | PROF | RCS |
|---|---|---|
| Price | $5.82 | $5.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 277.7K | 140.9K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.12% |
| EPS Growth | ★ 25.89 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $16,098,000.00 | N/A |
| Revenue This Year | $115.41 | N/A |
| Revenue Next Year | $60.63 | N/A |
| P/E Ratio | $3.67 | ★ N/A |
| Revenue Growth | ★ 50.73 | N/A |
| 52 Week Low | $3.90 | $5.24 |
| 52 Week High | $8.95 | $8.00 |
| Indicator | PROF | RCS |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 40.31 |
| Support Level | $5.38 | N/A |
| Resistance Level | $5.98 | $5.98 |
| Average True Range (ATR) | 0.52 | 0.15 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 48.63 | 31.03 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.